Amarantus Posts Review of MANF Literature to Web Site

Before you go, we thought you'd like these...
Before you go close icon

Amarantus Posts Review of MANF Literature to Web Site

SUNNYVALE, Calif.--(BUSINESS WIRE)-- Amarantus BioScience Holdings, Inc. (OTCQB: AMBS), a biotechnology company discovering and developing treatments and diagnostics for diseases associated with neurodegeneration and apoptosis, has posted to its Web site a White Paper titled "A Review of MANF Literature:Implications for the Development Program of Amarantus Bioscience Holdings." The White Paper can be found at http://ir.stockpr.com/amarantus/scientific-publications.

"This extensive report on our lead therapeutic MANF is valuable to a number of audiences, including life science research professionals, potential development partners, and investors as they conduct due diligence to better understand the breadth of the technology," said Amarantus Chief Executive Officer Gerald Commissiong. "It is the most comprehensive discussion of the properties and potential of MANF, and we believe it will significantly enhance understanding of our MANF therapeutic program."


Prepared by the consulting firm NeuroAssets, the 41-page report covers MANF's protein structure and cellular activities; studies related to Parkinson's disease, stroke, myocardial infarction and traumatic brain injury; and the potential for further development of MANF.

About Mesencephalic-Astrocyte-derived Neurotrophic Factor (MANF)

MANF (Mesencephalic-Astrocyte-derived Neurotrophic Factor) is believed to have broad potential because it is a naturally-occurring protein produced by the body for the purpose of reducing and preventing apoptosis (cell death) in response to injury or disease, via the unfolded protein response. By manufacturing MANF and administering it to the body, Amarantus is seeking to use a regenerative medicine approach to assist the body with higher quantities of MANF when needed. Amarantus is the front-runner and primary holder of intellectual property (IP) around MANF, and is initially focusing on the development of MANF-based protein therapeutics. MANF's current lead indication is Parkinson's disease with additional focus on Traumatic Brain Injury (TBI). Future indications may include myocardial infarction and certain rare and ultra-rare orphan diseases for which MANF is currently being evaluated.

About NeuroAssets

NeuroAssets identifies and manages the development of neuroscience assets that focus on diseases of the nervous and muscle systems. NeuroAssets was founded by David A. Lowe PhD, based on his extensive international experience of Nervous System R&D in Pharma, Biotech and Venture Capital Companies. The company is based in Vevey on Lake Geneva, Switzerland, and works with business partners in the U.S., Europe, Middle East and Asia. For further information please visit www.neuroassets.com.

About Amarantus

Amarantus is a development-stage biotechnology company founded in January 2008. The Company has a focus on developing certain biologics surrounding the intellectual property and proprietary technologies it owns to treat and/or diagnose Parkinson's disease, Traumatic Brain Injury, Ischemic Heart Disease and other human diseases. The Company owns the intellectual property rights to a therapeutic protein known as Mesencephalic-Astrocyte-derived Neurotrophic Factor ("MANF") and is developing MANF-based products as treatments for brain disorders. The Company also is a Founding Member of the Coalition for Concussion Treatment (#C4CT), a movement initiated in collaboration with Brewer Sports International seeking to raise awareness of new treatments in development for concussions and nervous-system disorders. The Company also owns intellectual property and licenses for the diagnosis of Parkinson's disease and Alzheimer's disease. For further information please visit www.Amarantus.com.

Forward Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements include, but are not limited to, statements about the possible progress of the MANF technology in testing for Parkinson's disease, as well as statements about expectations, plans and prospects of the development of Amarantus' diagnostic product candidates for Parkinson's and Alzheimer's disease. These forward-looking statements are subject to a number of risks, uncertainties and assumptions, including the risks associated with development of therapeutic drug candidates, as well as the risks, uncertainties and assumptions relating to the development of Amarantus' new product candidates, including those identified under "Risk Factors" in Amarantus' most recently filed Annual Report on Form 10-K and Quarterly Report on Form 10-Q and in other filings Amarantus periodically makes with the SEC. Actual results may differ materially from those contemplated by these forward-looking statements Amarantus does not undertake to update any of these forward-looking statements to reflect a change in its views or events or circumstances that occur after the date of this presentation.



Investor/Media Contacts
Amarantus
Russell Miller
Director of Investor Relations
310-386-2058
or
LHA
Don Markley, Senior Vice President
310-691-7100
dmarkley@lhai.com

KEYWORDS:   United States  North America  California

INDUSTRY KEYWORDS:

The article Amarantus Posts Review of MANF Literature to Web Site originally appeared on Fool.com.

Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

Copyright © 1995 - 2013 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.

Read Full Story

Want more news like this?

Sign up for Finance Report by AOL and get everything from business news to personal finance tips delivered directly to your inbox daily!

Subscribe to our other newsletters

Emails may offer personalized content or ads. Learn more. You may unsubscribe any time.

From Our Partners